Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Mesothelioma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1

Interventions

olaparib 6Specimen Handling 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 4Carboplatin 4pembrolizumab 3fludarabine 3X-Rays 3Taxes 3Metformin 3Letrozole 3Fluorodeoxyglucose F18 3Biopsy 3Aspirin 3niraparib 2Tirzepatide 2Radiotherapy 2Propranolol 2Platinum 2Pafolacianine 2Oncolytic Virotherapy 2Hysterectomy 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorescein 2Drug Therapy 2Doxorubicin 2Cytoreduction Surgical Procedures 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × amatuximab × Gynecologic × Clear all
NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡